Melanoma Research最新文献_第2页

Melanoma in the head and neck region: the value of preoperative imaging in melanoma stage I-II. 头颈部黑色素瘤：I-II期黑色素瘤术前影像学检查的价值

IF 1.5 4区医学

Melanoma Research Pub Date : 2025-04-01 Epub Date: 2024-12-03 DOI: 10.1097/CMR.0000000000001013

Sonja J Witteveen, W Martin C Klop, Margriet C van Dijk-de Haan, Luc H E Karssemakers

{"title":"Melanoma in the head and neck region: the value of preoperative imaging in melanoma stage I-II.","authors":"Sonja J Witteveen, W Martin C Klop, Margriet C van Dijk-de Haan, Luc H E Karssemakers","doi":"10.1097/CMR.0000000000001013","DOIUrl":"10.1097/CMR.0000000000001013","url":null,"abstract":"The management of head and neck melanoma (HNM) is constantly being fine-tuned in the era of immunotherapy. HNM have different metastatic patterns and a worse prognosis than melanoma of the trunk, asking for a more fine-tuned managing strategy. In clinically node-negative HNM patients, the ultrasound (US) with fine needle aspiration cytology (FNAC) and chest X-ray (CXR) are optional modalities in the preoperative staging workup. The contribution of imaging seems limited in this stage of disease. This study aims to research the value of the US-FNAC and CXR in clinically node-negative HNM patients. Clinical stage I-II HNM patients from 2016 to 2021 were retrospectively reviewed. A total of 373 patients were analyzed. Patient characteristics, surgery and follow-up details, recurrences, tumor characteristics, staging, imaging, sentinel node procedure (SNP) details, and lab results were collected from the patient files. All patients received preoperative US. A total of 65 FNACs were performed, which found metastatic lymph nodes in two patients (0.54%). The CXR was performed in 336/373 patients and did not find any pulmonary metastases. The SNP was performed in 242 patients and demonstrated 40 positive patients, with 86% having micrometastases, isolated tumor cells, or submicrometastases. This study demonstrated a low number of relevant findings by both the US and CXR. We can conclude that both imaging modalities do not have a significant contribution to the routine staging procedure of clinical stage I-II HNM in our study group, with our results being in line with current general melanoma guidelines.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"115-121"},"PeriodicalIF":1.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142780577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Steroid-refractory severe immune-related mucositis following adjuvant anti-PD-1 therapy for resectable melanoma: a case report.

IF 1.5 4区医学

Melanoma Research Pub Date : 2025-04-01 DOI: 10.1097/CMR.0000000000001037

Sidsel Pedersen, Troels Holz Borch, Inge Marie Svane, Marco Donia, Eva Ellebaek

{"title":"Steroid-refractory severe immune-related mucositis following adjuvant anti-PD-1 therapy for resectable melanoma: a case report.","authors":"Sidsel Pedersen, Troels Holz Borch, Inge Marie Svane, Marco Donia, Eva Ellebaek","doi":"10.1097/CMR.0000000000001037","DOIUrl":"https://doi.org/10.1097/CMR.0000000000001037","url":null,"abstract":"Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment and are increasingly used, also in the adjuvant and neoadjuvant settings. ICIs, however, can induce immune-related adverse events (irAEs), which range from mild to life-threatening. As the use of ICIs expands, prompt identification and management of especially severe and life-threatening irAEs are crucial. We report a case of grade 4 steroid-refractory immune-related mucositis in a 60-year-old male treated with pembrolizumab following complete resection of stage IIIC melanoma. The patient received seven courses of adjuvant pembrolizumab without adverse events until 2 weeks after the seventh dose, when he presented with acute respiratory distress, dysphagia, and dyspnea. Examination revealed significant throat swelling and mucosal edema. Despite initial treatment with high-dose steroids, the patient's condition deteriorated, and he was admitted to the ICU for intubation and close monitoring. Infliximab was administered for steroid-refractory mucositis, resulting in rapid symptom resolution and successful extubation 5 days later. This case highlights the challenges in managing severe steroid-refractory irAEs. The rapid response to infliximab suggests the benefit of early intervention with alternative immunosuppressive agents in severe irAEs. Increased awareness of rare irAEs is essential for optimizing treatment and improving outcomes for patients receiving ICIs.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143764480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A real-world direct cost associated with a 4-year postdiagnosis follow-up in a population-based cohort of patients with melanoma by clinical-pathological characteristics.

IF 1.5 4区医学

Melanoma Research Pub Date : 2025-03-28 DOI: 10.1097/CMR.0000000000001033

Alessandra Buja, Massimo Rugge, Carlo Maria Formaro, Giulia Grotto, Claudia Cozzolino, Antonella Stefano, Manuel Zorzi, Antonella Vecchiato, Paolo Del Fiore, Saveria Tropea, Chiara Trevisiol, Carlo Riccardo Rossi, Simone Mocellin

{"title":"A real-world direct cost associated with a 4-year postdiagnosis follow-up in a population-based cohort of patients with melanoma by clinical-pathological characteristics.","authors":"Alessandra Buja, Massimo Rugge, Carlo Maria Formaro, Giulia Grotto, Claudia Cozzolino, Antonella Stefano, Manuel Zorzi, Antonella Vecchiato, Paolo Del Fiore, Saveria Tropea, Chiara Trevisiol, Carlo Riccardo Rossi, Simone Mocellin","doi":"10.1097/CMR.0000000000001033","DOIUrl":"https://doi.org/10.1097/CMR.0000000000001033","url":null,"abstract":"In times of limited resources, data on the costs of disease should be one of the primary factors assisting policymakers in attaining the best value for money. This study aimed to analyze the real-world direct costs associated with a 4-year postdiagnosis follow-up of a population-based cohort of patients with cutaneous melanoma stratified by sociodemographic and clinical characteristics. The cost analysis was conducted from the perspective of the health system. Data on visits to outpatient clinics, specialist services, drug prescriptions, hospital or hospice admissions, and treatments at the emergency department were obtained from the regional administrative subject-level databases (see below). The cost of any diagnostic or therapeutic (surgical or otherwise) interventions was based on the reimbursement rates established by the Veneto Regional Authority. This study revealed that direct healthcare costs for patients with melanoma are associated with sociodemographic characteristics, that is, male gender and older age, and anatomopathological factors such as tumor-node-metastasis (TNM) stage, mitotic count, and growth pattern, with the highest costs occurring in vertical growth melanoma. Given the rising incidence of melanoma, the analysis of real-world direct costs for a population-based cohort of patients is essential for informing decision-makers on how to better allocate healthcare resources.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143753490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Do cortisol and psychological distress levels impact the effectiveness of immunotherapy in patients with metastasized melanoma? A pilot study.

IF 1.5 4区医学

Melanoma Research Pub Date : 2025-03-25 DOI: 10.1097/CMR.0000000000001035

Chris Hinnen, Frederiek Tijssens, Emma von Haeseler, Sjoerd van de Berg, Ellen Kapiteijn

引用次数: 0

Management of cardiac metastases of melanoma in the era of immunotherapy: a case series.

IF 1.5 4区医学

Melanoma Research Pub Date : 2025-03-25 DOI: 10.1097/CMR.0000000000001032

Mathilde Guyon, Maxime Faure, Mathieu Pernot, Anne Pham-Ledard, Océane Ducharme, Caroline Dutriaux, Sorilla Mary-Prey, Marie Beylot-Barry, Emilie Gerard

{"title":"Management of cardiac metastases of melanoma in the era of immunotherapy: a case series.","authors":"Mathilde Guyon, Maxime Faure, Mathieu Pernot, Anne Pham-Ledard, Océane Ducharme, Caroline Dutriaux, Sorilla Mary-Prey, Marie Beylot-Barry, Emilie Gerard","doi":"10.1097/CMR.0000000000001032","DOIUrl":"https://doi.org/10.1097/CMR.0000000000001032","url":null,"abstract":"Cardiac metastasis from melanoma is a rare but clinically significant condition often underdiagnosed because of its asymptomatic nature. This retrospective case series examines six patients with metastatic melanoma treated at the University Hospital of Bordeaux who were incidentally found to have cardiac metastases during follow-up. The patients were treated with immune checkpoint inhibitors (ICIs) either alone or combined with surgical excision of cardiac lesions. Outcomes were mixed, with three (50%) patients achieving a complete response, one (16.7%) a partial response, and two (33.3%) experiencing disease progression. Cardiac metastasectomy, when combined with ICI, showed promising results in selected patients, highlighting a potential survival benefit and enhanced tumor control with a multimodal approach. This series emphasizes the importance of considering cardiac metastases in differential diagnosis and underscores the role of imaging in early detection. While ICI therapy shows effectiveness, further studies are needed to refine treatment strategies and improve outcomes for patients with cardiac involvement.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143710759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nivolumab-induced immune-mediated acute gastritis in a melanoma patient. 一名黑色素瘤患者因免疫介导的急性胃炎而服用 Nivolumab。

IF 1.5 4区医学

Melanoma Research Pub Date : 2025-03-21 DOI: 10.1097/CMR.0000000000001034

Faruk Tas, Emel Ahishali, Orhun Cig Taskin

引用次数: 0

Diffuse large B-cell lymphoma mimicking metastatic melanoma: the importance of biopsies in the era of immune checkpoint inhibitors.

IF 1.5 4区医学

Melanoma Research Pub Date : 2025-02-27 DOI: 10.1097/CMR.0000000000001028

Sarah Janßen, Andrew Moufarrej, Robin Springer, Lena Häberle, Paul Jäger, Christina Antke, Bernhard Homey, Harm-Henning Lindhof

{"title":"Diffuse large B-cell lymphoma mimicking metastatic melanoma: the importance of biopsies in the era of immune checkpoint inhibitors.","authors":"Sarah Janßen, Andrew Moufarrej, Robin Springer, Lena Häberle, Paul Jäger, Christina Antke, Bernhard Homey, Harm-Henning Lindhof","doi":"10.1097/CMR.0000000000001028","DOIUrl":"10.1097/CMR.0000000000001028","url":null,"abstract":"Positron emission tomography (PET)/computed tomography (CT) imaging is an established tool in diagnosing and staging for various malignancies, however, during immune checkpoint inhibitor (ICI) therapy not only inflammatory changes may mimic disease progression, but also secondary malignancies should be considered in the setting of unusual clinical and radiographic findings. Here, we present the case of a 64-year-old man with a lymphogenic metastatic malignant melanoma treated with ipilimumab/nivolumab, in whom PET/CT indicated tumor progression of an intra-abdominal mass. Biopsy revealed an unusual reactive T-cell expansion without clonal expansion, pathologically consistent with ICI-induced immune response. As the patient's general condition worsened, we switched to targeted therapy, which had to be discontinued due to increasing fatigue. Follow-up PET/CT at 6 months showed further intra-abdominal progression. Subsequent histopathology of the extirpated mesenteric lymph node conglomerate now revealed diffuse large B-cell lymphoma. Our case highlights the importance of repeated histologic examinations of radiologic pathologies to distinguish secondary malignancies from ICI-induced inflammatory reactions or progressive disease.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143516084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multiple primary melanomas in Udine, northeastern Italy: a focus on epidemiology and new risk factors.

IF 1.5 4区医学

Melanoma Research Pub Date : 2025-02-27 DOI: 10.1097/CMR.0000000000001029

Alba Guglielmo, Alba De Benedittis, Cinzia Buligan, Enrico Zelin, Giuseppe Stinco

{"title":"Multiple primary melanomas in Udine, northeastern Italy: a focus on epidemiology and new risk factors.","authors":"Alba Guglielmo, Alba De Benedittis, Cinzia Buligan, Enrico Zelin, Giuseppe Stinco","doi":"10.1097/CMR.0000000000001029","DOIUrl":"https://doi.org/10.1097/CMR.0000000000001029","url":null,"abstract":"Patients diagnosed with melanoma are at an elevated risk of developing subsequent primary melanomas. The aim of this study was to assess the prevalence and identify the risk factors associated with multiple primary melanomas (MPMs) in patients referred to the melanoma outpatient service of the Dermatology Unit at the University Hospital of Udine, Italy. We conducted a retrospective analysis on patients with MPMs. For each patient demographic, clinical, and histological data were collected. For each excised melanoma, we recorded Breslow thickness, histological subtype, and anatomical site. A total of 233 patients with melanoma were included in the study, comprising a subgroup of 51 (22%) patients diagnosed with MPM. The mean Breslow thickness for patients with a single melanoma was significantly higher than the Breslow thickness for the first melanoma in the MPM subgroup. Furthermore, a statistically significant decrease in Breslow thickness between the first and second melanomas was observed. In our cohort, patients with MPM had a significantly higher prevalence of nonmelanoma skin cancers (NMSCs) compared with those with a single melanoma. Our study indicates that the prevalence of MPM in the province of Udine is among the highest reported globally. Our finding aligns with the broader literature, which consistently reports lower thickness in second melanoma compared with first melanoma. Finally, the higher prevalence of NMSC in these patients suggests a potential link to chronic ultraviolet exposure.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143516140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Patterns of expression and prognostic implication of glycoprotein nonmetastatic protein B (GPNMB) expression in sentinel lymph nodes of melanoma patients.

IF 1.5 4区医学

Melanoma Research Pub Date : 2025-02-14 DOI: 10.1097/CMR.0000000000001019

Ariel Beitner, Adam Abu-Abeid, Danit Dayan, Andrea Gat, Mor Miodovnik, Carmit Levy, Eran Nizri

{"title":"Patterns of expression and prognostic implication of glycoprotein nonmetastatic protein B (GPNMB) expression in sentinel lymph nodes of melanoma patients.","authors":"Ariel Beitner, Adam Abu-Abeid, Danit Dayan, Andrea Gat, Mor Miodovnik, Carmit Levy, Eran Nizri","doi":"10.1097/CMR.0000000000001019","DOIUrl":"https://doi.org/10.1097/CMR.0000000000001019","url":null,"abstract":"Sentinel lymph node biopsy (SLNB) is a critical procedure in the management of melanoma, offering prognostic information and guiding adjuvant therapy. Glycoprotein nonmetastatic melanoma protein B (GPNMB), a melanogenesis marker, has been implicated in melanoma progression. This study investigates the expression patterns of GPNMB in SLN metastases and their association with oncological outcomes. We conducted a retrospective analysis of 27 melanoma patients with positive SLNB at Tel Aviv Sourasky Medical Center between 2010 and 2020. Immunohistochemistry was used to assess GPNMB expression in SLN metastases, categorizing patients into two groups based on GPNMB expression patterns: homogeneous (GPNMBho) and margin high (GPNMBmh). Peri-tumoral CD8+ T cell infiltration was also evaluated. Clinical outcomes, including melanoma-specific survival (MSS) and disease-free survival (DFS), were analyzed. GPNMB expression in SLN metastases displayed two distinct patterns: uniform (GPNMBho) and high at the tumor margins (GPNMBmh). Patients in the GPNMBmh group had significantly more peri-tumoral CD8+ T cells and exhibited improved MSS (127.6, 95% CI: 111.7-143.5 vs 79.5, 95% CI: 48.2-110.9 months, P = 0.018) and DFS (107.5, 95% CI: 79-135.8 vs 38, 95% CI: 15.2-60.8 months, P = 0.04) compared to the GPNMBho group. Multivariate analysis confirmed that GPNMB expression pattern and lymph node metastasis size were independent predictors of both MSS and DFS. GPNMB expression patterns in SLN metastases are strongly associated with long-term oncological outcomes in melanoma patients. The GPNMBmh pattern, characterized by higher margin expression and increased CD8+ infiltration, may serve as a prognostic biomarker for recurrence if validated in larger cohorts.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143414598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

MHC class II: a predictor of outcome in melanoma treated with immune checkpoint inhibitors.

IF 1.5 4区医学

Melanoma Research Pub Date : 2025-02-12 DOI: 10.1097/CMR.0000000000001022

Karim Amrane, Pierre Le Noac'h, Patrice Hemon, Ronan Abgral, Coline Le Meur, Olivier Pradier, Laurent Misery, Delphine Legoupil, Christian Berthou, Arnaud Uguen

{"title":"MHC class II: a predictor of outcome in melanoma treated with immune checkpoint inhibitors.","authors":"Karim Amrane, Pierre Le Noac'h, Patrice Hemon, Ronan Abgral, Coline Le Meur, Olivier Pradier, Laurent Misery, Delphine Legoupil, Christian Berthou, Arnaud Uguen","doi":"10.1097/CMR.0000000000001022","DOIUrl":"https://doi.org/10.1097/CMR.0000000000001022","url":null,"abstract":"This study aimed to evaluate the predictive value of MHC class II (MHC-II) expression by melanoma cells in a large cohort of metastatic cutaneous melanoma patients treated with immune checkpoint inhibitors (ICIs). We conducted a single-center, retrospective study involving stage IV cutaneous melanoma patients who received ICI as first-line therapy. MHC-II expression in melanoma cells was quantified using dual-color anti-SOX10 and anti-MHC-II immunohistochemistry on tumor samples from 95 patients. The primary endpoint was event-free survival (EFS), with secondary endpoints including 1-year EFS, 1-year overall survival (OS), disease control rate (DCR), and the correlation between MHC-II expression and clinico-biological characteristics. The cohort had a median age of 67 years (range, 33-90), with a male-to-female ratio of 50 : 45. Thirty-three percent of patients received the ipilimumab-nivolumab combination. The median follow-up was 16.8 months. Disease progression occurred in 58 patients (61%), with a median time to progression of 4.8 months. Forty-six patients (48.4%) experienced an event within the first year, and 52 patients (54.7%) died during follow-up. MHC-II positivity was observed in ≥10% of melanoma cells in 6.3% of patients. MHC-II expression was significantly associated with 1-year EFS (P = 0.037) and DCR (P = 0.032), but not with EFS or 1-year OS. Age, phototype, and brain metastases were correlated with MHC-II expression status. Our findings suggest that MHC-II expression by melanoma cells may serve as a favorable predictive biomarker for survival in metastatic cutaneous melanoma patients treated with ICIs.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143409019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0